{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T13:14:56Z","timestamp":1770729296976,"version":"3.49.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ccell.2026.01.004","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T16:45:10Z","timestamp":1770655510000},"page":"254-256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enhancing therapeutic outcomes with artificial intelligence for HR-positive, HER2-negative metastatic breast cancer"],"prefix":"10.1016","volume":"44","author":[{"given":"Juan Luis","family":"Gomez Marti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Michaels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azadeh","family":"Nasrazadani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seth A.","family":"Wander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam M.","family":"Brufsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2026.01.004_bib1","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.01.004_bib2","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.01.004_bib3","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.01.004_bib4","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1158\/1078-0432.CCR-21-2947","article-title":"Mechanisms of resistance to CDK4\/6 blockade in advanced hormone receptor-positive, HER2-negative breast cancer and emerging therapeutic opportunities","volume":"28","author":"Lloyd","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2026.01.004_bib5","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41571-024-00935-6","article-title":"Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer","volume":"21","author":"Lloyd","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.01.004_bib6","first-page":"355","article-title":"Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+\/HER2\u2212 breast cancer: The LINUX trial","volume":"44","author":"Fan","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2026.01.004_bib7","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/s41588-023-01507-7","article-title":"Molecular classification of hormone receptor-positive HER2-negative breast cancer","volume":"55","author":"Jin","year":"2023","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ccell.2026.01.004_bib8","first-page":"S1676","volume":"36","author":"Mayer","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.01.004_bib9","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41571-024-00935-6","article-title":"Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer","volume":"21","author":"Lloyd","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610826000437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610826000437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T16:46:57Z","timestamp":1770655617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610826000437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1535610826000437"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2026.01.004","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancing therapeutic outcomes with artificial intelligence for HR-positive, HER2-negative metastatic breast cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2026.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2025.11.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}